Home

Ryan D Maynard

CIK 1363984 · Chief Financial Officer · last filed 2026-06-18

Ryan D Maynard is a Chief Financial Officer who has filed 41 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for IOVA, was dated Jun 18, 2026. Across all open-market trades the lifetime net is −$1.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $552.6K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$552.6K

Companies

5

Total Filings

41

Lifetime Open-Market Net

-$1.91M

Filer Profile

Reported Address
IOVANCE BIOTHERAPEUTICS, INC.
825 INDUSTRIAL ROAD, SUITE 100
SAN CARLOS, CA 94070
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
IOVA Director 7,500 $8.79 $65.9K -$452.4K 12 2026-06-18
FHTX Chief Financial Officer — $4.92 — $0 1 2026-02-24
Tvardi Therapeutics, Inc. (CARA) Delisted CHIEF FINANCIAL OFFICER 223 $15.96 $3.6K -$2.9K 4 2024-02-12
RIGL EVP & CFO 10,000 $48.67 $486.7K -$1.45M 19 2017-11-07
IOVANCE BIOTHERAPEUTICS, INC. (LBIO) Delisted Director — — — $0 3 2017-06-05

Recent Filings

41 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-18 IOVA Grant (A) — $0 EDGAR
2026-02-24 FHTX Grant (A) — $0 EDGAR
2025-06-17 IOVA Grant (A) — $0 EDGAR
2024-11-14 IOVA Mixed — -$130.5K EDGAR
2024-11-12 IOVA Notice (144) −50,000 -$503.1K EDGAR
2024-06-13 IOVA Grant (A) — $0 EDGAR
2024-03-05 IOVA Grant (A) — $0 EDGAR
2024-02-12 Tvardi Therapeutics, Inc. (CARA) Delisted Sell (S) −5,488 -$2.9K EDGAR
2024-02-05 Tvardi Therapeutics, Inc. (CARA) Delisted Grant (A) +13,500 $0 EDGAR
2023-06-08 IOVA Grant (A) — $0 EDGAR
Showing 1–10 of 41
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.